C07K16/22

Precision medicine for cholesterol treatment
11555066 · 2023-01-17 · ·

The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Precision medicine for cholesterol treatment
11555066 · 2023-01-17 · ·

The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

ANTIBODIES SPECIFICALLY RECOGNIZING NERVE GROWTH FACTOR AND USES THEREOF
20230220057 · 2023-07-13 ·

Provided are antibodies including antigen-binding fragment thereof that specifically recognizing Nerve Growth Factor NGF). Also provided are methods of making and using these antibodies.

ANTIBODIES SPECIFICALLY RECOGNIZING NERVE GROWTH FACTOR AND USES THEREOF
20230220057 · 2023-07-13 ·

Provided are antibodies including antigen-binding fragment thereof that specifically recognizing Nerve Growth Factor NGF). Also provided are methods of making and using these antibodies.

CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF
20230008052 · 2023-01-12 ·

Clonal strains of vaccinia viruses are provided. Also provided are methods of identifying and isolating attenuated and oncolytic clonal strains from virus preparations. Modified recombinant forms of the clonal strains also are provided. The clonal strains and virus preparations can be used for diagnostic and therapeutic methods, in particular for therapy and diagnosis or monitoring treatment of proliferative disorders, including neoplastic diseases, such as, but are not limited to, solid tumors and blood cancers.

CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF
20230008052 · 2023-01-12 ·

Clonal strains of vaccinia viruses are provided. Also provided are methods of identifying and isolating attenuated and oncolytic clonal strains from virus preparations. Modified recombinant forms of the clonal strains also are provided. The clonal strains and virus preparations can be used for diagnostic and therapeutic methods, in particular for therapy and diagnosis or monitoring treatment of proliferative disorders, including neoplastic diseases, such as, but are not limited to, solid tumors and blood cancers.

Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells

A method of modifying a glycosylation pattern of a polypeptide-of-interest in a plant or plant cell is provided. The method comprising expressing in a plant or plant cell transformed to express at least one glycosidase in a subcellular compartment, a nucleic acid sequence encoding the polypeptide-of-interest, such that the at least one glycosidase and the polypeptide-of-interest are co-localized to the subcellular compartment of the plant or plant cell, thereby modifying the glycosylation pattern of the polypeptide-of-interest in the plant or plant cell.

Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells

A method of modifying a glycosylation pattern of a polypeptide-of-interest in a plant or plant cell is provided. The method comprising expressing in a plant or plant cell transformed to express at least one glycosidase in a subcellular compartment, a nucleic acid sequence encoding the polypeptide-of-interest, such that the at least one glycosidase and the polypeptide-of-interest are co-localized to the subcellular compartment of the plant or plant cell, thereby modifying the glycosylation pattern of the polypeptide-of-interest in the plant or plant cell.

Viscosity-reducing compounds for protein formulations

The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.

Viscosity-reducing compounds for protein formulations

The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.